ONCOLOGY Vol 38, Issue 6

Misako Nagasaka, MD, PhD, discussed the approval of amivantamab plus chemotherapy for patients with EGFR exon 20 insertion mutations non–small cell lung cancer.

Tammy McClellan, PharmD, discusses the use of amivantamab plus chemotherapy in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

The June Hot Topics focuses on the challenges venetoclax regimens have faced in multiple myeloma trials.

"Anything that you can do to leverage technology to minimize the variability in surgery eliminates the skill gap so that novice surgeons may become as technically gifted as the intermediate surgeon or the master surgeon."

Johnathan Q. Trinh, MD, et al discuss a novel case of a patient with an aggressive CDKN2A-mutated spiradenocarcinoma who responded to a CDK4/6 inhibitor.

Neil M. Iyengar, MD, focuses on the use of artificial intelligence in the oncology space.